Advertisement
Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How a rare drug made from scientists' blood saves babies from botulism - 2Investigate These Retreats Well known With Seniors
- 3What's going on with Katseye? The Manon Bannerman hiatus drama, explained.
- 44 Coolers for Present day Kitchens
- 5Mystery foot suggests a second early human relative lived alongside Lucy
- Bullets in Luigi Mangione’s bag convinced police that he was UnitedHealthcare CEO killing suspect
- Figure out How to Adjust Work, Life, and an Internet based Degree
- Vote In favor of Your Favored Sort Of Dress
- Brazil's Bolsonaro to continue his sentence at home because of poor health
- New law puts familiar drinks, creams and gummies in legal limbo
- Vote in favor of your favored spot to peruse
- Chevron Says Damage at Wheatstone LNG Will Hamper Restart
- 7 Heavenly Espressos, One Do You Like?
- Gauging the Upsides and downsides of Visas: A Complete Aide
